Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GPN Reports Positive Safety and Immunogenicity Data from Phase 1 Trial of Gamma-PN
Details : Gamma-PN3 is a non-adjuvanted whole cell-pneumococcal vaccine. It is under phase 1/2 clinical development for the treatment of Pneumococcal Infections.
Product Name : Gamma-PN3
Product Type : Vaccine
Upfront Cash : Inapplicable
March 01, 2024
Lead Product(s) : Gamma-PN3
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable